2022 promised to be a big year for sickle cell disease, and this year’s Ash meeting will see updated results on Crispr and Vertex’s already impressive exa-cel, more data on Bluebird’s lovo-cel, and results from a handful of patients treated with therapies from the likes of Sangamo and Novartis.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,